FY2025 EPS Estimates for Insmed Lifted by Leerink Partnrs

Key Points

• Leerink Partners has raised its FY2025 earnings estimates for Insmed, forecasting a loss of ($5.51) per share, an improvement from their previous estimate of ($5.55).
• Insmed reported a 18.9% year-over-year increase in revenue to $107.42 million, despite missing earnings expectations with a reported EPS of ($1.70).
• Several analysts have upgraded their ratings, with Insmed receiving multiple "buy" ratings and price objectives increasing to as high as $171.00.

Insmed, Inc. (NASDAQ:INSM - Free Report) - Investment analysts at Leerink Partnrs raised their FY2025 earnings estimates for Insmed in a note issued to investors on Monday, September 1st. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings of ($5.51) per share for the year, up from their prior forecast of ($5.55). The consensus estimate for Insmed's current full-year earnings is ($4.56) per share. Leerink Partnrs also issued estimates for Insmed's Q1 2026 earnings at ($1.20) EPS, Q2 2026 earnings at ($1.08) EPS, Q3 2026 earnings at ($0.97) EPS, Q4 2026 earnings at ($0.86) EPS, FY2026 earnings at ($4.11) EPS and FY2027 earnings at ($2.51) EPS.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same quarter in the previous year, the company posted ($1.94) earnings per share. Insmed's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS.

Several other equities research analysts also recently commented on the stock. Citigroup raised shares of Insmed to a "buy" rating in a research note on Tuesday, June 10th. Truist Financial increased their price objective on shares of Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Bank of America increased their price objective on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. JPMorgan Chase & Co. increased their price objective on shares of Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 20th. Finally, Wells Fargo & Company increased their price objective on shares of Insmed from $140.00 to $171.00 and gave the stock an "overweight" rating in a research report on Wednesday. Sixteen analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $134.79.

Insmed Stock Down 1.2%

Shares of NASDAQ:INSM opened at $143.50 on Thursday. Insmed has a 52 week low of $60.40 and a 52 week high of $146.84. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The company has a market capitalization of $30.33 billion, a PE ratio of -25.13 and a beta of 0.97. The company has a 50 day moving average price of $112.91 and a two-hundred day moving average price of $88.79.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Norges Bank acquired a new position in shares of Insmed during the 2nd quarter valued at $194,728,000. Adage Capital Partners GP L.L.C. lifted its position in shares of Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock valued at $262,967,000 after acquiring an additional 1,799,382 shares during the period. Orbis Allan Gray Ltd acquired a new position in shares of Insmed during the 2nd quarter valued at $153,389,000. Nuveen LLC acquired a new position in shares of Insmed during the 1st quarter valued at $88,351,000. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Insmed during the 2nd quarter valued at $108,898,000.

Insider Transactions at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the firm's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total value of $9,264,648.24. Following the transaction, the insider directly owned 89,407 shares of the company's stock, valued at $8,352,401.94. This trade represents a 52.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Melvin Md Sharoky sold 10,000 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $129.50, for a total value of $1,295,000.00. Following the transaction, the director directly owned 274,516 shares of the company's stock, valued at approximately $35,549,822. The trade was a 3.51% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 511,048 shares of company stock worth $51,089,294. Corporate insiders own 3.00% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.